Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$24.66 - $34.8 $167,688 - $236,639
-6,800 Reduced 47.22%
7,600 $263,000
Q1 2024

May 15, 2024

SELL
$21.79 - $32.15 $884,674 - $1.31 Million
-40,600 Reduced 73.82%
14,400 $416,000
Q4 2023

Feb 14, 2024

BUY
$14.05 - $23.44 $428,525 - $714,920
30,500 Added 124.49%
55,000 $1.26 Million
Q3 2023

Nov 14, 2023

SELL
$16.68 - $23.66 $882,372 - $1.25 Million
-52,900 Reduced 68.35%
24,500 $408,000
Q2 2023

Aug 14, 2023

SELL
$18.02 - $29.36 $88,298 - $143,864
-4,900 Reduced 5.95%
77,400 $2.14 Million
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $620,928 - $1.46 Million
57,600 Added 233.2%
82,300 $1.89 Million
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $181,792 - $275,899
24,700 New
24,700 $269,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.